Cargando…
Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
Autores principales: | Müntze, Jonas, Salinger, Tim, Gensler, Daniel, Wanner, Christoph, Nordbeck, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963304/ https://www.ncbi.nlm.nih.gov/pubmed/29452394 http://dx.doi.org/10.1093/eurheartj/ehy072 |
Ejemplares similares
-
Dual apical hypertrophic cardiomyopathy and endomyocardial fibrosis pathology
por: Martini, Chiara, et al.
Publicado: (2023) -
Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
por: Müntze, Jonas, et al.
Publicado: (2019) -
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
por: Müntze, Jonas, et al.
Publicado: (2019) -
Exuberant late gadolinium enhancement in hypertrophic cardiomyopathy as a precursor to ‘burn out’
por: Gweun, John, et al.
Publicado: (2022) -
Value of the CHA(2)DS(2)-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
por: Liu, Dan, et al.
Publicado: (2018)